Quick Answer
Estrella Immunopharma, Inc. reported R&D Expense of $10.25 million for fiscal year 2025.
Estrella Immunopharma, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $10.25M | +149.4% |
| 2024 | $4.11M | -60.7% |
| 2023 | $10.45M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.15M | +46.9% | -10.9% |
| June 30, 2025 | $4.66M | +32.2% | +230.5% |
| March 31, 2025 | $1.41M | +5540.8% | -50.1% |
| September 30, 2024 | $2.83M | +484.5% | -19.8% |
| June 30, 2024 | $3.52M | — | +14000.0% |
| March 31, 2024 | $25.0K | -99.0% | -66.9% |
| December 31, 2023 | $75.5K | -97.1% | -84.4% |
| September 30, 2023 | $483.5K | -81.4% | -81.6% |
- Estrella Immunopharma, Inc. showed an increase of +149.4% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, Estrella Immunopharma, Inc.’s r&d expense has declined by 1.9% (from $10.45 million to $10.25 million).
- The most recent figure is from Estrella Immunopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: